Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03991130
Recruitment Status : Recruiting
First Posted : June 19, 2019
Last Update Posted : August 28, 2020
Sponsor:
Information provided by (Responsible Party):
Gregory Daniels, University of California, San Diego

Brief Summary:
The primary objective of this single arm phase 2 trial is to assess the response rate [complete response (CR) + partial response (PR)] of combined nivolumab and HD IL-2 in subjects with metastatic melanoma and renal cell carcinoma. Response will be performed after each course of nivolumab and IL-2 using RECIST 1.1. Patients will be treated for one course past best response for a maximum of 3 courses.

Condition or disease Intervention/treatment Phase
Melanoma Stage Iv Renal Cell Carcinoma, Metastatic Drug: IL-2 and Nivolumab Phase 2

Detailed Description:

PrimaryObjective Determine the overall response rate (complete response and partial response) for patients receiving anti-PD-1 (nivolumab) and high dose IL-2 (HD IL-2) in subjects with metastatic melanoma or renal cell carcinoma who have previously progressed on anti-PD-1 therapy. Response assessment will be performed using revised RECIST guideline (v 1.1).

Secondary Objectives

  • Characterize safety, tolerability and adverse effects (AE) profile of nivolumab with HD IL-2 in subjects with metastatic malignant melanoma or renal cell carcinoma
  • Measure Progression-Free Survival (PFS) using RECIST 1.1 after completion of at least one course of therapy (2 doses of nivolumab, 2 cycles of HD IL-2) for subjects enrolled in the study.

ExploratoryObjectives

  • Correlate PD-L1 expression and tumor mutational burden (TMB) in archived diagnostic tumor tissue with best clinical response for subjects with metastatic melanoma and renal cell carcinoma
  • Correlate myeloid-derived suppressor cells and T-cell subsets in peripheral blood during therapy with best clinical response (RECIST criteria) and treatment outcome in subjects with metastatic melanoma or renal cell carcinoma. Data will be collected prior to each treatment and after each course of treatment.

Study Duration: 48 months Amount of Subjects: up to 25 subjects

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
Actual Study Start Date : May 23, 2019
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : August 2024


Arm Intervention/treatment
Experimental: High Dose IL-2 and Nivolumab Drug: IL-2 and Nivolumab
Course length will be 35 days. Subjects will receive 480 mg IV of nivolumab on day 1 of the cycle. The patient will be admitted to UCSD Jacobs Medical center for standard HD IL-2 which will be administered every 8 hrs for up to 14 doses days 8-12 per institutional practice. The patient will be readmitted days 22-28 for HD IL-2 every 8 hrs for up to 14 doses. Nivolumab 480 mg IV will be administered day 35. Scans for response will occur 4 weeks after day 35 nivolumab dose and response will be determined by RECIST 1.1 to determine if the patient will receive the next course.
Other Names:
  • High Dose IL-2
  • Anti-PD-1




Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: 3 years post treatment ]
    The primary endpoint will be the response rate [complete response (CR) and partial response (PR)] of combined therapy with nivolumab and HD IL-2 in metastatic melanoma and renal cell carcinoma and will be evaluated using revised RECIST 1.1. Response rate will be computed with associated 95% confidence intervals.


Secondary Outcome Measures :
  1. Drug Toxicity [ Time Frame: After Initiation of a 35 day study treatment period up to 90 days following the last administration of study treatment ]
    Proportion of subjects with each grade of adverse events as defined by CTCAE v 5.0 will be computed. Toxicity will be reported in a tabular and descriptive manner.

  2. Progression Free Survival [ Time Frame: 1 year +/- 3 months ]
    • Median PFS times will be calculate and PFS rate at 1 year +/- 3 months will be calculated with associated 95% confidence intervals based on the Kaplan-Meier method.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has the ability to understand and the willingness to sign a written informed consent.
  • Age ≥ 18 years at the time of consent.
  • At least 6 weeks of prior anti-PD-1 therapy with documented clinical or radiographic progression. Last anti-PD-1 therapy must be within 6 months of enrollment.
  • Histologically-confirmed diagnosis of unresectable stage III or metastatic (stage IV) melanoma or renal cell carcinoma
  • Measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1, and obtained by imaging within 28 days prior registration for protocol therapy.
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 28 days prior to registration for protocol therapy.
  • Adequate hepatic function within 28 days prior to registration for protocol therapy defined as meeting all of the following criteria:
  • total bilirubin ≤ 1.5 × upper limit of normal (ULN) OR direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 x ULN (except in patients with Gilbert's syndrome who must have a total bilirubin less than 3.0 mg/dl.)

    • and aspartate aminotransferase (AST) ≤ 2.5 × ULN or ≤ 5 × ULN for subjects with known hepatic metastases
    • and alanine aminotransferase (ALT) ≤ 2.5 × ULN or ≤ 5 × ULN for subjects with known hepatic metastases
  • Adequate renal function within 28 days prior to registration for protocol therapy defined by either of the following criteria:

    • Serum creatinine ≤ 1.5 mg/dL
    • OR if serum creatinine > 1.5 mg/dL, estimated glomerular filtration rate (GFR) ≥ 50 mL/min
  • Adequate hematologic function within 28 days prior to registration for protocol therapy defined as meeting all of the following criteria:

    • hemoglobin ≥ 9.0 g/dL
    • and absolute neutrophil count (ANC) ≥ 1000/L without the support of filgrastim
    • white blood cells (WBC) ≥ 3000/L
    • and platelet count ≥ 100 × 109/L
  • Adequate coagulation functioning within 28 days prior to registration for protocol therapy defined by either of the following criteria:

    • INR < 1.5 × ULN
    • OR for subjects receiving warfarin or LMWH, the subjects must, in the investigator's opinion, be clinically stable with no evidence of active bleeding while receiving anticoagulant therapy. The INR for these subjects may exceed 1.5 × ULN if that is the goal of anticoagulant therapy.
  • Adequate pulmonary and cardiac function for HD IL-2 (will be assessed clinically)
  • Female subjects of childbearing potential must have confirmed negative urine or serum pregnancy test prior to drug administration and be willing to use two methods of birth control.
  • Male subjects who are not surgically sterile (vasectomy) must agree to use an adequate method of contraception.
  • Subject's toxicities from prior treatments must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)

Exclusion Criteria:

  • Active infection requiring systemic therapy
  • Women who are pregnant or breastfeeding.
  • Second active malignancy within the past 5 years with the exception of localized basal or squamous cell skin cancer, in situ cervical or bladder cancer, or localized prostate cancer under active surveillance.
  • Active symptomatic central nervous system (CNS) metastases. Prior treated metastases or asymptomatic metastases are allowed. Patient can receive radiation between treatments if deemed medically necessary.
  • Surgery within 4 weeks prior to study treatment except for minor procedures.
  • Uncontrolled or poorly-controlled hypertension (> 160 mmHg systolic or > 100 mmHg diastolic for > 4 weeks) despite standard medical management.
  • Serious or non-healing wounds, ulcers, or bone fractures within 28 days prior to initiation of study treatment.
  • Any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to initiation of study treatment.
  • Has any condition that, in the opinion of the investigator, might jeopardize the safety of the patient or interfere with protocol compliance.
  • Has any mental or medical condition that prevents the patient from giving informed consent or participating in the trial.
  • Known hypersensitivity to nivolumab or IL-2 or any of their components.
  • Known history of active tuberculosis.
  • Concurrent systemic steroid therapy with doses above physiologic level (more than 10 mg of prednisone daily).
  • Active autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, granulomatosis with polyangiitis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis requiring treatment. Patients cannot be on immunosuppressive medications other than physiologic replacement doses of prednisone (less than 10 mg per day at enrollment) or equivalent steroid. Asymptomatic patients or those stable on non-immunosuppressive medications are eligible.
  • Treatment with any investigational agent within 21 days prior to initiation of study treatment and the subject must have recovered from the acute toxic effects of the regimen with the exception of prior anti-PD-1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03991130


Contacts
Layout table for location contacts
Contact: Gregory Daniels, MD, PhD 858-246-2706 gdaniels@ucsd.edu
Contact: Jaren Mullen 858-822-6176 jmullen@ucsd.edu

Locations
Layout table for location information
United States, California
UC San Diego Moores Cancer Center Recruiting
La Jolla, California, United States, 92093
Contact: Jaren Mullen    858-822-6176    jmullen@ucsd.edu   
Contact: Yael Cohen-Arazi    858-822-5354    ycohenarazi@ucsd.edu   
Principal Investigator: Mina Nikanjam, MD, PhD         
Sub-Investigator: Gregory A. Daniels, MD, PhD         
Sponsors and Collaborators
Gregory Daniels
Layout table for additonal information
Responsible Party: Gregory Daniels, Assistant Clinical Professor, University of California, San Diego
ClinicalTrials.gov Identifier: NCT03991130    
Obsolete Identifiers: NCT03889782
Other Study ID Numbers: UCSD IIT HD IL-2
First Posted: June 19, 2019    Key Record Dates
Last Update Posted: August 28, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gregory Daniels, University of California, San Diego:
melanoma
renal cell carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Melanoma
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents